ifenprodil has been researched along with Parkinsonian Disorders in 1 studies
ifenprodil: NMDA receptor antagonist
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of NR2B antagonists in Parkinsonism is still controversial." | 1.42 | The NR2B antagonist, ifenprodil, corrects the l-DOPA-induced deficit of bilateral movement and reduces c-Fos expression in the subthalamic nucleus of hemiparkinsonian rats. ( Akita, H; Habata, T; Igarashi, M; Noda, K; Ogata, M; Saji, M, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Igarashi, M | 1 |
| Habata, T | 1 |
| Akita, H | 1 |
| Noda, K | 1 |
| Ogata, M | 1 |
| Saji, M | 1 |
1 other study available for ifenprodil and Parkinsonian Disorders
| Article | Year |
|---|---|
The NR2B antagonist, ifenprodil, corrects the l-DOPA-induced deficit of bilateral movement and reduces c-Fos expression in the subthalamic nucleus of hemiparkinsonian rats.
Topics: Animals; Antiparkinson Agents; Brain; Forelimb; Levodopa; Male; Motor Activity; Parkinsonian Disorde | 2015 |